ReviewAnnals of translational medicine2023
Serological diagnosis of myasthenia gravis and its clinical significance.
Review in Annals of translational medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Can Non-Thymomatous Late-Onset Myasthenia Gravis Benefit From Thymectomy? A Systematic Review and Meta-Analysis.European journal of neurology · 2025Pooled it
- Review
- Comprehensive review on myasthenia gravis: patho-physiology, diagnosis, management strategies.Wiener medizinische Wochenschrift (1946) · 2026Review
- Italian recommendations for the diagnosis and treatment of myasthenia gravis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Article
- The immune microenvironment and population heterogeneity in myasthenia gravis: implications for precision therapeutics.Frontiers in immunology · 2026Review
- Olfactory Dysfunction in Patients With Acetylcholine-Receptor-Antibody-Positive Myasthenia Gravis.Journal of clinical neurology (Seoul, Korea) · 2025Article
- Therapeutic strategies targeting complement in myasthenia gravis patients.Journal of neurology · 2025Review
- Review
- Clinical features of myasthenia gravis with thyroid eye disease: identifying critical gaps and next steps.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Article
- An unusual initiation of an ocular form of MuSK-positive myasthenia gravis after magnesium administration: a rare case report.Annals of medicine and surgery (2012) · 2024Article
- Inter-laboratory comparison of routine autoantibody detection methods for autoimmune neuropathies and myasthenia gravis.Journal of neurology · 2024Article
- A Bead-Based Nonradioactive Immunoassay for Autoantibody Testing in a Mouse Model of Myasthenia Gravis.Antibodies (Basel, Switzerland) · 2024Article
- Should We Consider Routine Blood Work for Diplopia and Ptosis in a Primary Care Setting?Cureus · 2024Article
- Triple-seronegative myasthenia gravis: clinical and epidemiological characteristics.Arquivos de neuro-psiquiatria · 2024Article
- Detection of Autoantibodies Against the Acetylcholine Receptor, Evaluation of Commercially Available Methodologies: Fixed Cell-Based Assay, Radioimmunoprecipitation Assay and Enzyme-Linked Immunosorbent Assay1.Journal of neuromuscular diseases · 2024Article
- A Focus on Myasthenic Ptosis: The Interface of Medical and Surgical Treatment.World journal of plastic surgery · 2024Review
- Depression: A Contributing Factor to the Clinical Course in Myasthenia Gravis Patients.Medicina (Kaunas, Lithuania) · 2023Article
- Myasthenia Gravis: A Systematic Review.Cureus · 2023Review
- Review
- Case Report: Telitacicept in severe myasthenia gravis: a case study with multiple autoantibodies.Frontiers in immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myasthenia gravis (MG) is the most common immune-mediated disorder of the neuromuscular junction. Anti-acetylcholine receptor (anti-AChR), anti-muscle-specific kinase (anti-MuSK), and anti-lipoprotein receptor-related protein 4 (anti-LRP4) antibodies are the three well-defined pathogenic antibodies. Patients with MG can also have other antibodies, such as anti-titin, anti-ryanodine receptor (anti-RyR), anti-Agrin and anti-KV1.4 antibodies. Since MG is heterogeneous in terms of pathophysiology, antibody status, and other factors, serological tests are crucial for clinical diagnosis confirmation and treatment choice. Herein, we review the different methods for detection of various antibodies involved in MG and their sensitivity and specificity. The understanding of these elements should be useful for improving the diagnosis and determining how to adapt the existing therapies to the requirements of each patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.